* Aardvark Therapeutics press release [https://seekingalpha.com/pr/20200202-aardvark-therapeutics-reports-second-quarter-2025-financial-results-and-provides-pipeline-and] (NASDAQ:AARD [https://seekingalpha.com/symbol/AARD]): Q2 GAAP EPS of -$0.66.
* As of June 30, 2025, Aardvark had cash, cash equivalents, and short-term investments of $141.8 million. Based on current operating plans, Aardvark believes that its existing cash, cash equivalents, and short-term investments will be sufficient to fund projected operations into 2027.
*
MORE ON AARDVARK THERAPEUTICS
* Historical earnings data for Aardvark Therapeutics [https://seekingalpha.com/symbol/AARD/earnings]
* Financial information for Aardvark Therapeutics [https://seekingalpha.com/symbol/AARD/income-statement]
Aardvark Therapeutics GAAP EPS of -$0.66
Published 2 months ago
Aug 13, 2025 at 9:05 PM
Neutral
Auto